Search
Recursion Pharmaceuticals Inc
RXRXAdd to Watchlist
4.055USD
+0.255+6.71%
Market hours 10/27, 12:52（ET）
2.41BMarket Cap
LossP/E TTM
Recursion Pharmaceuticals Inc (RXRX) Stock Price Target & Forecast
Analyst Rating
Based on 7 analysts giving stock ratings to Recursion Pharmaceuticals Inc in the past month.
Hold
0 Strong Buy
3 Buy
4 Hold
0 Sell
0 Strong Sell
Target Price
6.780USD+78.42%
RXRX Analyst Recommendation Trends
In the current month, RXRX has received 3 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. RXRX average Analyst price target in the last month is 6.780.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
0
0
0
0
0
0
0
0
3
3
3
3
3
3
3
3
4
4
4
5
5
5
5
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
7
7
8
8
8
8
8
RXRX Analyst Rating for Peer Comparison
Updated: Oct 27, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
15
5
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
Cytokinetics Inc
CYTK
5
16
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
11
8
0
0
23
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
Financial Forecasting
Based on analysts' estimates, RXRX EPS is projected to reach -0.230 in FY2026Q3, following reported EPS of -0.246 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.32
-0.27
-0.23
-0.23
-0.23
Actual
-0.21
-0.22
-0.25
--
--
Surprise
+34.37%
+18.21%
-5.15%
--
--
FAQs
What is Recursion Pharmaceuticals Inc's expected revenue for the next quarter?
Recursion Pharmaceuticals Inc's expected revenue is 13.01M.
What is Recursion Pharmaceuticals Inc's price target?
Analysts forecast that Recursion Pharmaceuticals Inc's price target is USD 6.78, with the highest forecast at USD 10.00 and the lowest forecast at USD 4.00.
How have Recursion Pharmaceuticals IncRXRX's recent earnings per share performed?
The market expectation was USD -0.25, while Recursion Pharmaceuticals IncRXRX's earnings per share (EPS) for the previous quarter was USD -0.22. EPS for the next quarter is expected at USD -0.23.
What is the analyst rating for Recursion Pharmaceuticals Inc?
Based on the ratings of Recursion Pharmaceuticals Inc's stock from 7 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.